Not with our compounds. A close read of the poster shows 2-73, under those lab in-vivo research test conditions, is a relatively mediocre S1 agonist, and that 3-71 is a bit better. (That was of course not the point of the research. The point was to help elucidate what S1 receptors do and how.)
Seeing that, what will convince potential partners (domestically, internationally, whatever) is clinical success.
Market Data 
Markets 
AI
